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Abstract
Background: Arterial and venous thrombosis are both common in antiphospholipid 
syndrome (APS). Recent studies have shown that anti- factor Xa (FXa) therapy in APS 
patients leads to a greater number of patients with arterial thrombosis than with war-
farin. We hypothesize that this may be due to the lowering of prothrombin levels by 
warfarin.
Objectives: To investigate whether antiprothrombin antibodies induce platelet ag-
gregation and to identify the platelet receptors involved. A second aim was to inves-
tigate the effect of reduced prothrombin levels on antiprothrombin antibody- induced 
platelet aggregation.
Methods: Enzyme- linked immunosorbent assays were performed to measure bind-
ing of antiprothrombin antibodies to prothrombin fragment 1+2 and prothrombin. 
Platelet aggregation assays in washed platelets were performed. FcγRIIA was immu-
noprecipitated and tyrosine- phosphorylated FcγRIIA was measured by western blot.
Results: The antiprothrombin antibodies 28F4 and 3B1 had lupus anticoagulant (LAC) 
activity and caused platelet aggregation in the presence of Ca2+ and prothrombin. 
Antiprothrombin antibodies without LAC activity did not activate platelets. Inhibition 
of Syk and Src kinases and FcγRIIA blocked platelet aggregation. Fab and F(ab’)2 frag-
ments of 28F4 were unable to induce platelet aggregation. Immunoprecipitations 
showed that whole 28F4 immunoglobulin G induced tyrosine phosphorylation of 
FcγRIIA. Platelet aggregation was significantly reduced when prothrombin levels were 
reduced from 1 µM to 0.2 µM.
Conclusions: Antiprothrombin antibodies with LAC activity are able to activate 
platelets via FcγRIIA. Decreased prothrombin levels resulted in less antiprothrombin 
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1  |  INTRODUC TION
Antiphospholipid syndrome (APS) is characterized by thrombosis 
and/or pregnancy complications due to the persistent presence of 
antiphospholipid antibodies.1 Laboratory criteria for classification 
of APS include detection of lupus anticoagulant (LAC), anti- β2- 
glycoprotein I (aβ2GPI) and anticardiolipin (aCL) immunoglobulin G 
(IgG)/M antibodies.1 Clinical criteria for classification of thrombotic 
APS include venous, arterial, and small vessel thrombosis. The up-
dated European League Against Rheumatism recommendations on 
managing thrombotic APS patients recommend long- term vitamin K 
antagonists as the standard of care.2
Direct oral anticoagulants (DOACs) such as rivaroxaban, a direct 
factor Xa (FXa) inhibitor, are currently prescribed to patients with 
venous thromboembolism and atrial fibrillation. The advantage of 
DOACs is that they are given at a fixed dose and do not need labora-
tory monitoring. Interestingly, two trials reported predominantly ar-
terial thrombosis in patients treated with rivaroxaban with a high rate 
of stroke.3,4 No cases of stroke were reported in patients treated with 
warfarin.3,4 Recent professional guidance statements have been issued 
regarding the use of DOACs in APS patients and recommended against 
DOACs in triple positive APS patients (defined by the presence of LAC, 
aβ2GPI, and aCL antibodies) and in arterial thrombosis.5
Blood platelets play a key role in arterial thrombosis.6 Antibodies 
against β2GPI are known to activate platelets via glycoprotein (GP) 
Ibα and apolipoprotein E receptor 2.7,8 Triple- positive APS patients 
have the highest risk of thrombotic complications, and these patients 
usually have both aβ2GPI antibodies and anti- phosphatidylserine/pro-
thrombin (aPS/PT) antibodies.9 A systematic review identified aPS/PT 
antibodies as a risk factor for arterial thrombosis.10 Still, experimental 
data on aPS/PT antibodies and platelet aggregation are lacking.
The overall aim was to investigate whether antiprothrombin an-
tibodies stimulate platelet activation and to identify the underlying 
mechanism. This included investigation of the effect of reduced 
prothrombin levels on platelet aggregation as warfarin inhibits the 
vitamin K– dependent synthesis of biologically active prothrombin, 
whereas DOACs do not.11 Decreased levels of prothrombin may ex-
plain why warfarin- treated APS patients are protected against ar-
terial thrombosis, whereas those treated with rivaroxaban are not.
2  |  MATERIAL AND METHODS
2.1  |  Reagents
Purified human prothrombin was from Synapse Research Institute 
(Maastricht, The Netherlands) and rivaroxaban (Xarelto) was from 
Bayer Schering Pharma AG. Anti- FcγRIIA monoclonal antibody (mAb) 
IV.3 was purified in the laboratory from a hybridoma.12 The antipro-
thrombin mAb 28F4 is a mouse IgG antibody, as described previ-
ously.13,14 Antiprothrombin fragment 1+2 mAbs 3B1, 6A3, 11H2, and 
8H11 were developed and produced according to standard proce-
dures.15 LAC was measured by activated partial thromboplastin time 
(Diagnostica Stago), dilute Russell Viper Venom Time (Diagnostica 
Stago), and Ecarin Clotting Time (ECT; Diagnostic Reagents). The 
Pierce Classic IP Kit from Thermo Fisher Scientific was used for im-
munoprecipitation. High- binding enzyme- linked immunosorbent 
assay (ELISA) plates from Costar were used for the ELISAs. Sheep 
anti- human prothrombin IgG horseradish peroxidase– labeled anti-
body was from Affinity Biologicals, Inc., prothrombin fragment 1+2 
was from Haematologic Technologies, Inc. All other reagents are 
previously described or are from Sigma- Aldrich.16
2.2  |  Preparation of washed platelets
Blood was drawn by venipuncture into 4% sodium citrate and then, 
within 5 min of blood draw, mixed with 10% acidic citrate dextrose 
antibody- mediated platelet aggregation. This may explain the lower incidence of arte-
rial thrombosis in patients treated with warfarin than with anti- FXa therapy.
K E Y W O R D S
antiphospholipid syndrome, antiprothrombin antibodies, DOACs, thrombosis, vitamin K 
antagonists
Essentials
• Arterial and venous thrombosis are both common in antiphospholipid syndrome and this is 
linked to the presence of antiprothrombin antibodies.
• Antiprothrombin antibodies with lupus anticoagulant activity are able to activate platelets via 
the FcγRIIA receptor.
• Decreased prothrombin levels resulted in less antiprothrombin antibody- mediated platelet 
aggregation.
• The reduction in antiprothrombin levels by warfarin may explain the lower incidence of arte-
rial thrombosis in patients than with anti- FXa therapy.
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(120 mM sodium citrate, 110 mM glucose, 80 mM citric acid) from 
consenting, self- reported healthy volunteers. Platelet- rich plasma 
was obtained by centrifugation at 200g for 20 min at room tem-
perature. Washed platelets were obtained by further centrifuga-
tion of platelet- rich plasma at 1000g for 10 min in the presence 
of 0.2 μg/ml prostacyclin and resuspended in modified- Tyrode's- 
HEPES buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 
12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, 1 mM MgCl2; pH 
7.3), as previously described.16 Platelets were used at 2 × 108/ml 
and 4 × 108/ml for aggregation studies and immunoprecipitation, 
respectively.
2.3  |  Fab and F(ab′)2 antibody fragments
Fab fragments from 28F4 were generated by 4- h incubation of 
5 mg/ml antibody with immobilized Ficin in the presence of 25 mM 
cysteine (Pierce, ThermoFisher) at 37°C. F(ab′)2 fragments from 
28F4 were generated by 24- h incubation of 5 mg/ml antibody with 
immobilized Ficin in the presence of 4 mM cysteine (Pierce) at 37°C. 
Preparations were then applied to an immobilized protein A column 
(Pierce) followed by dialysis to remove any remaining cysteine. The 
purity of the Fab and F(ab′)2 fragments was verified by sodium dode-
cyl sulphate– polyacrylamide gel electrophoresis.
2.4  |  Lupus anticoagulant testing
Normal pooled plasma was incubated with 50 µg/ml mAb for 
10 min at 37°C before LAC testing. LAC was performed according 
to the SSC guidelines and manufacturer's instructions for ECT were 
followed.17,18
2.5  |  ELISA
The mAb 28F4 (5 µg/ml) was coated onto an ELISA plate over-
night at 4°C. Blocking buffer consisted of 5% bovine serum albu-
min and 5 mM CaCl2 in Tris- buffered saline (pH 7.6). Washing buffer 
was 5 mM CaCl2 and 0.1% Tween in Tris- buffered saline (pH 7.6). 
Increasing concentrations of antigen (prothrombin fragment 1+2, 
purified prothrombin, or platelet- poor plasma) was incubated for 
1 h at room temperature. Sheep anti- human prothrombin IgG 
horseradish peroxidase- labeled antibody (1:1000) was used as sec-
ondary antibody followed by staining with tetra methyl benzidine 
(ThermoFisher). The reaction was stopped with 2 M H2SO4 and ab-
sorption was measured at 405 nm.
2.6  |  Platelet aggregation assay
Platelet aggregation was assessed by light transmission aggregom-
etry in a PAP- 8E (Bio/Data Corporation) aggregometer for up to 
30 min. Washed platelets were incubated with aPT antibodies for 
5 min with an antiprothrombin antibody (50 μg/ml) followed by 
CaCl2 (1 mM, 3 mM, or 10 mM) and purified human prothrombin 
(1 µM). In some studies, platelets were preincubated with eptifiba-
tide (9 µM), vorapaxar (1 µM) + BMS- 986120 (1 µM), indomethacin 
(10 µM), ticagrelor (10 µM), PRT- 060318 (5 µM), dasatinib (10 µM), 
mAb IV.3 (10 µg/ml), or rivaroxaban (200, 400, 800, or 1000 nM) 
for 10 min.
2.7  |  Immunoprecipitation and western blotting
Washed platelets were pretreated with 9 μM eptifibatide to block 
integrin αIIbβ3. Cross- linking of IV.3 IgG (10 µg/ml) with 10 µg/
ml anti- Fc (Biolegend) served as a positive control. Platelets were 
stimulated at 37°C with stirring at 1200 rpm on a PAP- 8E ag-
gregometer. Reactions were terminated by addition of ice- cold lysis 
buffer (0.025 M Tris, 0.15 M NaCl, 0.001 M EDTA, 1% NP- 40, 5% 
glycerol, pH 7.4). Lysates were incubated overnight with mAb IV.3 
to form immune complexes. Precipitated proteins were separated 
by reducing sodium dodecyl sulphate– polyacrylamide gel electro-
phoresis, electro- transferred, and Western blotted with the anti- 
phosphotyrosine antibody, clone 4G10.
2.8  |  Ethics
Ethical approval for collecting blood healthy volunteers was granted 
by Birmingham University Internal Ethical Review (ERN_11- 0175).
2.9  |  Statistical analysis
All data are presented as mean ± standard deviation (SD). A p- value 
<.05 was considered statistically significant. Statistical analysis was 
performed using Wilcoxon signed- rank test, Kruskal- Wallis test 
with Dunn's multiple comparison test and Mann- Whitney U test 
as stated. All statistical analyses were performed using GraphPad 
Prism 7 (GraphPad Software Inc.).
3  |  RESULTS
3.1  |  Lupus anticoagulant activity
The five antiprothrombin mAbs (28F4, 3B1, 6A3, 11H2, and 8H11) 
were raised against F1+2, the activation peptide of prothrombin. 
Of these mAbs, only 28F4 and 3B1 caused LAC activity in the di-
lute Russell Viper Venom Time and activated partial thromboplas-
tin time tests. The other three mAbs (11H2, 6A3, and 8H11) had 
no effect on the clotting time (Table S1). The ECT reagent con-
verts prothrombin into thrombin, independently of phospholip-
ids. The mAbs 28F4 and 3B1 did not prolong the ECT and did not 
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inhibit thrombin activity when tested with a fluorescent substrate. 
However, mAb 28F4 did bind to prothrombin fragment 1+2, puri-
fied prothrombin, and native prothrombin in plasma in an ELISA 
assay (Figure S1).
3.2  |  Platelet aggregation
Adding mAbs 28F4 and 3B1, but not 11H2, 6A3, and 8H11, resulted 
in aggregation of washed platelets in the presence of prothrombin 
and 10 mM Ca2+ (Figure 1A), indicating a correlation between LAC 
activity and platelet aggregation. mAb 28F4 induced aggregation in 
washed platelets in the presence but not absence of Ca2+ (data not 
shown) or prothrombin (Figure S2). The 28F4 also induced platelet 
aggregation in the presence lower Ca2+ concentrations (1 mM Ca2+ 
and 3 mM Ca2+; Figure S3). 28F4 was the most potent at inducing 
platelet aggregation and LAC activity. Preincubation of washed 
platelets with 1 µg/ml 28F4 resulted in partial aggregation. Full 
platelet aggregation was achieved with 10 µg/ml 28F4. Addition of 
200– 1000 nM rivaroxaban to washed platelets did not influence the 
aggregation profile.
3.3  |  Platelet signalling
Inhibitors were used to investigate the mechanism involved in 
antiprothrombin- induced platelet aggregation to low (10 µg/ml) and 
high (50 µg/ml) concentrations of mAb 28F4. Pretreatment of plate-
lets with the αIIbβ3 antagonist eptifibatide inhibited platelet aggre-
gation to both concentrations of mAb 28F4 (Table 1). Indomethacin 
and ticagrelor, which block cyclooxygenase and the P2Y12 receptor, 
respectively, attenuated but did not block platelet aggregation. 
Platelet aggregation induced by mAb 28F4 was not altered in the 
combined presence of the PAR- 1 and PAR- 4 antagonists, vorapaxar, 
and BMS- 986120, respectively. The same concentrations of the two 
antagonists blocked thrombin mediated platelet aggregation (data 
not shown). The Syk and Src inhibitors, PRT- 060318 and dasatinib, 
respectively, blocked aggregation to both concentrations of mAb 
28F4, which indicates involvement of signalling via receptors con-
taining an immunoreceptor tyrosine- based activation motif (ITAM). 
Three ITAM- containing receptors of human platelets are known in-
cluding: C- type lectin- like receptor 2, GPVI, and FcγRIIA (Fc receptor 
for IgG).
3.4  |  Involvement of FcγRIIA
Of the three platelet ITAM- containing receptors, FcγRIIA re-
ceptor was felt to be the most likely to be involved in the re-
sponse to the antiprothrombin antibodies because it is a low 
affinity receptor for the Fc domain. Tyrosine phosphorylation 
of FcγRIIA was induced by mAb 28F4 as measured by immu-
noprecipitation and western blotting (Figure 2). Crosslinked 
IV.3 (α- FcγRIIA antibody) was used as a positive control. As 
expected, rhodocytin and CRP, known stimulators of C- type 
lectin- like receptor 2 and GPVI, respectively, did not result 
in tyrosine phosphorylation of FcγRIIA. Non- crosslinked mAb 
IV.3 showed a trend toward inhibiting 28F4- and 3B1- induced 
platelet aggregation (Figure 3 and not shown). Fab and F(ab′)2 
antibody fragments of mAb 28F4 were unable to induce plate-
let aggregation (not shown) confirming the critical role of the 
Fc domain.
F I G U R E  1  The mAbs 28F4 and 3B1 induce platelet aggregation in the presence of Ca2+ and prothrombin. (A) Representative traces of 
light transmission aggregometry using washed platelets at a concentration of 2 × 108/ml. Aliquots of platelet suspension were stimulated 
with 50 µg/ml of mAbs 28F4, 3B1, 6A3, 11H2, or 8H11 in the presence of 10 mM Ca2+ and 1 µM prothrombin (n = 3). (B) Quantification of 
platelet aggregation induced by increasing doses of mAb 28F4. Platelet aggregation was measured as increase of light transmission. Results 
are shown as mean ± SD (n = 3). Statistical significance was analyzed using the Kruskal- Wallis test. *p < .05. mAbs, monoclonal antibodies; 
NS, not significant
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3.5  |  The link between prothrombin levels and 
platelet aggregation
We investigated whether prothrombin levels affected mAb 28F4- 
induced platelet aggregation as a possible explanation for anti- FXa 
therapy failure in patients with APS. Platelet aggregation was as-
sessed in washed platelets in the presence of 50 µg/ml 28F4 with 
two concentrations of prothrombin. Aggregation was found to be at-
tenuated by 59% when prothrombin levels were reduced from 1 µM 
to 0.2 µM, suggesting a direct link between prothrombin levels and 
platelet aggregation (Figure 4).
4  |  DISCUSSION
In this study, we show that (1) antiprothrombin antibodies with LAC 
activity, but not those without LAC activity, are able to activate 
platelets via the FcγRIIA receptor; and (2) decreased prothrombin 
levels result in less antiprothrombin antibody- mediated platelet ag-
gregation. These results suggest an important role of antiprothrom-
bin antibodies with LAC activity in platelet activation. We speculate 
that the LAC activity is required for binding of the prothrombin/
antiprothrombin complex to the platelet surface leading to binding 
of the Fc portion of the antiprothrombin antibodies to FcγRIIA and 
platelet activation.
Antiprothrombin antibodies with LAC activity are associated 
with APC resistance.19 We were able to demonstrate platelet ag-
gregation caused by antiprothrombin antibodies with LAC activ-
ity, indicating that antiprothrombin antibodies with LAC activity 
are potentially pathogenic. Antiprothrombin antibodies can be 
detected by coating prothrombin on irradiated ELISA plates or 
using phosphatidylserine– prothrombin complex as antigen.10 The 
TA B L E  1  ITAM signaling is involved in antiprothrombin induced 
platelet aggregation
28F4 (10 µg/ml) 28F4 (50 µg/ml)
% Aggregation ± SD % Aggregation ± SD
Vehicle 65.4 ± 10.2 70.0 ± 8.1
Eptifibatide (9 µM) 4.5 ± 1.4 18.0 ± 9.2
Indomethacin (10 µM) 22.3 ± 11.2 38.9 ± 18.2
PRT- 06318 (5 µM) 2.5 ± 2.8 3.9 ± 1.8
Ticagrelor (10 µM) 11.0 ± 6.0 19.6 ± 15.7
Dasatinib (10 µM) 2.7 ± 1.7 4.2 ± 2.6
Vorapaxar (1 µM) + 
BMS- 986120 (1 µM)
65.8 ± 2.3 74.6 ± 4.1
Note: Low dose of mAb 28F4 (10 µg/ml) and high dose of mAb 28F4 
(50 µg/ml) was used to assess the effect of platelet antagonists. Platelet 
aggregation was measured as increase of light transmission. Results are 
shown as mean ± standard deviation (SD) (n = 3).
F I G U R E  2  FcγRIIA is tyrosine- phosphorylated in the presence of mAb 28F4. (A) Representative blot of five experiments. (B) Mean data 
of signal for p- FcγRIIA. The signal obtained from crosslinked mAb IV.3 was normalized against total FcγRIIA and set as a reference (1 AU). 
Differences were analyzed with the Kruskal- Wallis test. Results are shown as mean ± SD with n = 5. *p < .05. mAb, monoclonal antibody;   
NS, not significant
F I G U R E  3  Antiprothrombin- induced platelet aggregation can 
be blocked by mAb IV.3 (anti- FcγRIIA) antibody. Aliquots of platelet 
suspension were preincubated with mAb IV.3 (10 µg/ml) followed 
by stimulation using mAbs 28F4 (50 µg/ml) or 3B1 (50 µg/ml). 
Platelet aggregation was measured as increase of light transmission. 
Results are shown as mean ± SD (n = 5). Statistical significance 
was analyzed using the Mann- Whitney U test (*p < .05). mAb, 
monoclonal antibody; SD, standard deviation
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presence of aPS/PT antibodies is considered to be a stronger predic-
tor of thrombosis than antiprothrombin antibodies.10 However, we 
demonstrated binding of mAb 28F4 to prothrombin in the absence 
of phosphatidylserine, by ELISA. A recent study showed that at least 
two subpopulations of aPS/PT antibodies exist; aPS/PT antibodies 
that bind to the “open” conformation of prothrombin and aPS/PT 
antibodies able to react with “closed” prothrombin.20 There were, 
however, no different pathological effects found between the two 
subpopulations of aPS/PT antibodies. In contrast, we were able to 
distinguish between antiprothrombin antibodies that were able to 
induce platelet aggregation and those that did not by measuring LAC 
activity. From the five antiprothrombin antibodies investigated, only 
mAbs 28F4 and 3B1 were able to induce platelet aggregation and 
LAC activity. Although mAb 28F4 is able to bind closed prothrombin, 
thrombin activity was not inhibited, which could be explained by the 
affinity of the investigated mAbs toward the activation peptide of 
prothrombin, fragment 1+2, and not thrombin. These data indicate 
that LAC activity determines the ability of antiprothrombin antibod-
ies to induce platelet aggregation.
Data on the role of antiprothrombin antibodies in platelet acti-
vation are limited, probably because platelet aggregation studies are 
performed in citrated plasma and prothrombin needs Ca2+ to bind to 
platelets.21 Although platelet function assays were not performed, 
one study showed the potency of mAb 28F4 to induce platelet ac-
tivation by measuring thromboxane B2 levels, phospholipid- related 
platelet procoagulant activity, and thrombin generation.19 The 
platelet- dependent effect of mAb 28F4 was found to be reduced in 
the presence of an integrin αIIbβ3 inhibitor, but not with IV.3.19 The 
inability of showing involvement of the FcγRIIA receptor might be due 
to the low concentration of mAb IV.3 used in their study.19 We have 
showed involvement of the FcγRIIA receptor in mAb 28F4 induced 
platelet activation in three ways: (1) inhibited platelet aggregation 
by IV.3; (2) tyrosine phosphorylation of the FcγRIIA receptor; and (3) 
the inability of Fab and F(ab′)2 fragments of mAb 28F4 to aggregate 
platelets. In this respect, the mechanism of platelet activation by aPT 
antibodies mimics another autoimmune disease; heparin- induced 
thrombocytopenia and thrombosis.22 The presence of Ca2+ proved 
to be essential for platelet aggregation induced by antiprothrombin 
antibodies, suggesting Ca2+- dependent binding of antiprothrombin- 
prothrombin immune complexes to negatively charged phospholip-
ids expressed by platelets. Here, we show a major role for FcγRIIA in 
antiprothrombin- induced platelet aggregation.
The trial of rivaroxaban in antiphospholipid syndrome trial in-
cluded APS patients with exclusively triple positive antiphospholipid 
(LAC, aCL and aβ2GPI antibodies) in which rivaroxaban was com-
pared with warfarin therapy.3 Although aPS/PT antibodies were not 
measured in the trial, aPS/PT antibodies have shown to correlate 
well with triple positivity in other studies.20,23 We found that platelet 
aggregation was attenuated when prothrombin levels were reduced. 
The link between prothrombin levels and platelet aggregation may 
explain the failure of anti- FXa therapy in patients with APS as ri-
varoxaban does not affect prothrombin levels in plasma, whereas 
vitamin K antagonists (e.g., warfarin) reduce active prothrombin (an-
tigen) levels.
There are several limitations in our study. We used mAbs that 
recognize the prothrombin F1+2 fragment, but we did not fur-
ther specify the site of recognition. In addition, we did not con-
firm our findings with patient antibodies and did not evaluate 
antiprothrombin- induced platelet activation in patients receiving 
vitamin K antagonists or rivaroxaban therapy. Additional data are 
needed on the specification of antiprothrombin antibodies and their 
effect on platelets.
Here, we have shown that only antiprothrombin antibodies with 
LAC activity are able to activate platelets via the FcγRIIA receptor. 
Decreased prothrombin levels resulted in attenuated platelet ag-
gregation, which might be an explanation for the low prevalence of 
arterial thrombosis in APS patients treated with warfarin compared 
with rivaroxaban therapy.
F I G U R E  4  Decreased prothrombin levels results in attenuated platelet aggregation. (A) Representative traces of light transmission 
aggregometry using washed platelets at a concentration of 2 x 108/ml. Aliquots of platelet suspension were preincubated with 0.2 μM 
prothrombin or 1 μM prothrombin, followed by stimulation using 50 μg/ml mAb 28F4. (B) Quantification of platelet aggregation in the 
presence of two concentrations of prothrombin. Platelet aggregation was measured as increase of light transmission. Results are shown as 
mean ± SD (n = 5). Statistical significance was analyzed using the Mann- Whitney U test (*p < 0.05). SD, standard deviation
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